4G/5G polymorphism of plasminogen activator inhibitor -1 gene is associated with mortality in intensive care unit patients with severe pneumonia

Anesthesiology

Volumn 110, Issue 5, 2009, Pages 1086-1091

  Sapru, Anil ^a   Hansen, Helen ^b   Ajayi, Temitayo ^b   Brown, Ron ^b   Garcia, Oscar ^b   Zhuo, HanJing ^b   Wiemels, Joseph ^b   Matthay, Michael A ^b   Wiener Kronish, Jeanine ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLOOD SAMPLING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; DNA ISOLATION; DNA POLYMORPHISM; FEMALE; FOLLOW UP; GENOTYPE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOGENESIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; VENTILATOR; AGED; COMPARATIVE STUDY; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; TRANSPOSON;

ADULT; AGED; COHORT STUDIES; DNA TRANSPOSABLE ELEMENTS; FEMALE; HOSPITAL MORTALITY; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PNEUMONIA; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES;

EID: 65549105461     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e3181a1081d     Document Type: Article

References (32)

1. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman HA: Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322:890-7
2. Choi G, Schultz MJ, van Till JW, Bresser P, van der Zee JS, Boermeester MA, Levi M, van der Poll T: Disturbed alveolar fibrin turnover during pneumonia is restricted to the site of infection. Eur Respir J 2004; 24:786-9
3. Determann RM, Millo JL, Garrard CS, Schultz MJ: Bronchoalveolar levels of plasminogen activator inhibitor-1 and soluble tissue factor are sensitive and specific markers of pulmonary inammation. Intensive Care Med 2006; 32:946-7
4. Gunther A, Mosavi P, Heinemann S, Ruppert C, Muth H, Markart P, Grimminger F, Walmrath D, Temmesfeld-Wollbruck B, Seeger W: Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000; 161:454-62
5. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS: Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84:695-705
6. Nakstad B, Lyberg T, Skjonsberg OH, Boye NP: Local activation of the coagulation and fibrinolysis systems in lung disease. Thromb Res 1990; 57: 827-38
7. Vadasz I, Morty RE, Olschewski A, Konigshoff M, Kohstall MG, Ghofrani HA, Grimminger F, Seeger W: Thrombin impairs alveolar uid clearance by promoting endocytosis of Na-,K-ATPase. Am J Respir Cell Mol Biol 2005; 33:343-54
8. Schultz MJ, Millo J, Levi M, Hack CE, Weverling GJ, Garrard CS, van der Poll T: Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia. Thorax 2004; 59:130-5
9. El Solh AA, Bhora M, Pineda L, Aquilina A, Abbetessa L, Berbary E: Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis. Intensive Care Med 2006; 32:110-5
10. Horrevoets AJ: Plasminogen activator inhibitor 1 (PAI-1): In vitro activities and clinical relevance. Br J Haematol 2004; 125:12-23
11. Gunther A, Mosavi P, Ruppert C, Heinemann S, Temmesfeld B, Velcovsky HG, Morr H, Grimminger F, Walmrath D, Seeger W: Enhanced tissue factor pathway activity and fibrin turnover in the alveolar compartment of patients with interstitial lung disease. Thromb Haemost 2000; 83:853-60
12. Song Y, Lynch SV, Flanagan J, Zhuo H, Tom W, Dotson RH, Baek MS, Rubio-Mills A, Singh G, Kipnis E, Glidden D, Brown R, Garcia O, Wiener-Kronish JP: Increased plasminogen activator inhibitor-1 concentrations in bronchoalveolar lavage uids are associated with increased mortality in a cohort of patients with Pseudomonas aeruginosa. ANESTHESIOLOGY 2007; 106:252-61
13. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA: Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema uid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285:L20-8
14. Ware LB, Matthay MA, Parsons PE, Thompson BT, Januzzi JL, Eisner MD: Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. Crit Care Med 2007; 35:1821-8
15. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM: The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-45
16. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, Levin M: 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354:556-60
17. Yende S, Angus DC, Ding J, Newman AB, Kellum JA, Li R, Ferrell RE, Zmuda J, Kritchevsky SB, Harris TB, Garcia M, Yaffe K, Wunderink RG: 4G/5G plasminogen activator inhibitor-1 polymorphisms and haplotypes are associated with pneumonia. Am J Respir Crit Care Med 2007; 176:1129-37
18. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, Dean N, File T, Fine MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54
19. Schoenfeld D: Statistical evaluation of ventillator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. Crit Care Med 2002; 30:1772-7
20. Livak KJ: Allelic discrimination using uorogenic probes and the 5= nuclease assay. Genet Anal 1999; 14:143-9
21. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-55
22. Tsangaris I, Tsantes A, Bonovas S, Lignos M, Kopterides P, Gialeraki A, Rapti E, Orfanos S, Dimopoulou I, Travlou A, Armaganidis A: The impact of the PAI-1 4G/5G polymorphism on the outcome of patients with ALI/ARDS. Thromb Res 2008, Sept. 19 [Epub ahead of print]
23. Eriksson P, Kallin B, van ǎ"t Hooft FM, Bavenholm P, Hamsten A: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad SciUSA 1995; 92:1851-5
24. Hoekstra T, Geleijnse JM, Schouten EG, Kluft C: Plasminogen activator inhibitor-type 1: Its plasma determinants and relation with cardiovascular risk. Thromb Haemost 2004; 91:861-72
25. Chapman HA: Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 1997; 9:714-24
26. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC, Fuller JA, Toews GB: Urokinase is required for the pulmonary inammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Invest 1996; 97:1818-26
27. Rijneveld AW, Florquin S, Bresser P, Levi M, DeWaard V, Lijnen R, Van Der Zee JS, Speelman P, Carmeliet P, Van Der Poll T: Plasminogen activator inhibitor type-1 deficiency does not inuence the outcome of murine pneumococcal pneumonia. Blood 2003; 102:934-9
28. Sitrin RG, Shollenberger SB, Strieter RM, Gyetko MR: Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by THP-1 mononuclear phagocytes. J Leukoc Biol 1996; 59:302-11 29. Sitrin RG, Todd RF 3rd, Albrecht E, Gyetko MR: The urokinase receptor (CD87) facilitates CD11b/CD18-mediated adhesion of human monocytes. J Clin Invest 1996; 97:1942-51
29. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA: Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J Clin Invest 1997; 100:58-67
30. Tejerina E, Frutos-Vivar F, Restrepo MI, Anzueto A, Palizas F, Gonzalez M, Apezteguia C, Abroug F, Matamis D, Bugedo G, Esteban A: Prognosis factors and outcome of community-acquired pneumonia needing mechanical ventilation. J Crit Care 2005; 20:230-8
31. Pippins JR, Fitzmaurice GM, Haas JS: Hospital characteristics and racial disparities in hospital mortality from common medical conditions. J Natl Med Assoc 2007; 99:1030-6
32. Kathiresan S, Gabriel SB, Yang Q, Lochner AL, Larson MG, Levy D, Toer GH, Hirschhorn JN, Oǎ™Donnell CJ: Comprehensive survey of common genetic variation at the plasminogen activator inhibitor-1 locus and relations to circulating plasminogen activator inhibitor-1 levels. Circulation 2005; 112:1728-35